Can the Board please provide a more detailed explanation of the significance of the clinical study results reported to the ASX on 9 March 2018, and in particular: (1) What is the short-term and long-term commercial significance of these results for the Company; (2) Have the results of the study been presented to any pharmaceutical companies and, if so, how have these results been received by those companies?; (3) Does the Board anticipate further clinical trials being conducted by such companies pursuant to a formal agreement with OBJ? (4) What revenues, both short-term and long-term, does the Board foresee being derived from this application of the Company's magnetophoresis technology?
- Forums
- ASX - By Stock
- Questions for 5 April Investor Call
Can the Board please provide a more detailed explanation of the...
-
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online